Egis Pharmaceuticals's net debt stood at HUF -43,021 mil and accounted for -0.240 of equity at the end of 2012. The ratio is down 0.039 pp compared to the previous year.
Historically, the firm’s net debt to equity reached a high of < -0.001 in 2003 and a low of -0.240 in 2012 between 2000 and 2012. The average for the last five years was -0.141%.
Net debt to EBITDA was calculated at -1.41x at the end of the year. That is down from -0.492x seen in 2007. The ratio reached a high of -0.001x in 2003 and a low of -1.41x in 2012.
The company’s cost of funding amounted to 1.51% in 2012, down which is above the 5-year of 26.7%. Funding costs have “eaten” some 0.225% of the operating profit generated in 2019.
You can see all the company’s data at Egis Pharmaceuticals profile, or you can download a report on the company in the report section.
Helgi Library 
